Landau-Kleffner syndrome: A case report

To contribute to the growing body of literature on Landau-Kleffner Syndrome (LKS) by detailing its clinical and imaging features, therapeutic approaches, and clinical outcomes. 5-year-old, female, presented with sleep-related seizures beginning at age 3. At 5, she exhibited psychomotor regression, including loss of drawing skills, language regression, spatial disorientation, and disruptive behaviors such as aggression and attempts to flee. Initial treatment with phenobarbital and oxcarbazepine failed to control seizures. Sleep EEGs revealed a continuous spike-and-wave pattern, and cranial MRI was unremarkable. Based on these findings, LKS was diagnosed. Oxcarbazepine was discontinued, phenobarbital was maintained, and corticosteroid therapy with prednisolone (2 mg/kg/day) was introduced. After one month, she showed significant clinical improvement, including seizure cessation, improved motor function, and partial recovery of cognitive and visuospatial abilities. Subsequent EEGs showed persistent but reduced epileptiform activity. Prednisolone was gradually tapered, and clobazam (20 mg/day) was introduced. She has remained seizure-free for six months, with ongoing speech improvement. LKS is a rare pediatric neurological disorder characterized by acquired aphasia and epilepsy, often with electrographic abnormalities during sleep. Its etiology is multifactorial, involving genetic, immunologic, and inflammatory mechanisms. Diagnosis relies on clinical history, neurological exam, and sleep EEG. Management includes a combination of pharmacologic therapies (e.g., corticosteroids, antiepileptics, benzodiazepines) and supportive interventions like speech therapy. This case highlights the favorable clinical response to corticosteroids and clobazam in a child with LKS. Informed consent was obtained from the patient’s guardians. • Landau-Kleffner syndrome has a significant impact on affected children • There is no consensus on the treatment of this rare syndrome • The barriers of resources and a long distance from the reference center. • The diagnostic delay of the case

Authors

Institutions

Publication Details

Journal
Medical Reports
Published
2025-05-16
DOI
https://doi.org/10.1016/j.hmedic.2025.100247
Primary Topic
Mitochondrial Function and Pathology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Landau-Kleffner syndrome: A case report

Maria Luiza de Andrade Correia, Eugênio Grillo
Medical Reports
Mitochondrial Function and Pathology
article

Landau-Kleffner syndrome: A case report

Maria Luiza de Andrade Correia, Eugênio Grillo
article en

Abstract

To contribute to the growing body of literature on Landau-Kleffner Syndrome (LKS) by detailing its clinical and imaging features, therapeutic approaches, and clinical outcomes. 5-year-old, female, presented with sleep-related seizures beginning at age 3. At 5, she exhibited psychomotor regression, including loss of drawing skills, language regression, spatial disorientation, and disruptive behaviors such as aggression and attempts to flee. Initial treatment with phenobarbital and oxcarbazepine failed to control seizures. Sleep EEGs revealed a continuous spike-and-wave pattern, and cranial MRI was unremarkable. Based on these findings, LKS was diagnosed. Oxcarbazepine was discontinued, phenobarbital was maintained, and corticosteroid therapy with prednisolone (2 mg/kg/day) was introduced. After one month, she showed significant clinical improvement, including seizure cessation, improved motor function, and partial recovery of cognitive and visuospatial abilities. Subsequent EEGs showed persistent but reduced epileptiform activity. Prednisolone was gradually tapered, and clobazam (20 mg/day) was introduced. She has remained seizure-free for six months, with ongoing speech improvement. LKS is a rare pediatric neurological disorder characterized by acquired aphasia and epilepsy, often with electrographic abnormalities during sleep. Its etiology is multifactorial, involving genetic, immunologic, and inflammatory mechanisms. Diagnosis relies on clinical history, neurological exam, and sleep EEG. Management includes a combination of pharmacologic therapies (e.g., corticosteroids, antiepileptics, benzodiazepines) and supportive interventions like speech therapy. This case highlights the favorable clinical response to corticosteroids and clobazam in a child with LKS. Informed consent was obtained from the patient’s guardians. • Landau-Kleffner syndrome has a significant impact on affected children • There is no consensus on the treatment of this rare syndrome • The barriers of resources and a long distance from the reference center. • The diagnostic delay of the case

Medical ReportsVol. 13
Universidade Federal de Santa Catarina (BR)
Openalex Percentile: Top 90%
Mitochondrial Function and Pathology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.